

Title (en)
THE USE OF GLATIRAMER ACETATE (COPOLYMER 1) IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

Title (de)
VERWENDUNG VON GLATIRAMER ACETAT (COPOLYMER 1) ZUR BEHANDLUNG VON STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS

Title (fr)
UTILISATION D'ACETATE DE GLATIRAMERE (COPOLYMER 1) POUR TRAITER DES MALADIES DU SYSTEME NERVEUX CENTRAL

Publication
EP 1292279 A4 20050112 (EN)

Application
EP 01941973 A 20010605

Priority

- US 0118248 W 20010605
- US 58752300 A 20000605

Abstract (en)
[origin: WO0193828A1] The present invention involves the administration of Copolymer 1 (glatiramer acetate) to treat inflammatory, non-autoimmune central nervous system (CNS) diseases, alleviate the symptoms thereof, inhibit the activity of matrix metalloproteinases and suppress cytokine production by T lymphocytes.

IPC 1-7
A61K 9/00; **A61K 38/00**; **A61F 13/00**; **A61F 9/02**

IPC 8 full level
A61K 9/72 (2006.01); **A61K 31/785** (2006.01); **A61K 38/55** (2006.01); **A61K 45/00** (2006.01); **A61K 9/02** (2006.01); **A61P 25/00** (2006.01); **A61P 25/16** (2006.01); **A61P 25/28** (2006.01); **A61P 27/06** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)
A61K 31/785 (2013.01); **A61P 25/00** (2018.01); **A61P 25/16** (2018.01); **A61P 25/28** (2018.01); **A61P 27/06** (2018.01); **A61P 29/00** (2018.01); **A61P 31/04** (2018.01); **A61P 31/18** (2018.01); **A61P 35/00** (2018.01); **A61P 43/00** (2018.01)

Citation (search report)

- [E] WO 0193893 A2 20011213 - YEDA RES & DEV [IL], et al
- [E] WO 0152878 A2 20010726 - YEDA RES & DEV [IL], et al
- [A] WO 9531990 A1 19951130 - YEDA RES & DEV [IL], et al
- [A] AHARONI R ET AL: "COPOLYMER 1 INDUCES T CELLS OF THE T HELPER TYPE 2 THAT CROSSREACT WITH MYELIN BASIC PROTEIN AND SUPPRESS EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, September 1997 (1997-09-01), pages 10821 - 10826, XP002918836, ISSN: 0027-8424
- [A] AHARONI R ET AL: "COP 1 SPECIFIC SUPPRESSOR CELLS INHIBIT EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS INDUCED BY EITHER MOUSE SPINAL CORD HOMOGENATE OR PROTEOLIPID PROTEIN PEPTIDE 139-151", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 48, no. 3, SUPPL 2, 12 April 1997 (1997-04-12), pages A422, XP001029141, ISSN: 0028-3878
- [A] TEVA ET AL: "COPOLYMER-1 GLATIRAMER ACETATE COPAXONE(R) AGENT FOR MULTIPLE SCLEROSIS", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 23, no. 2, 1998, pages 213 - 214, XP001029138, ISSN: 0377-8282
- See also references of WO 0193828A1

Cited by
AU2001272956B2; AU2001272956B8; EP1301206A4; US7279172B2; US7615359B2; US7429374B2; US7163802B2; US7425332B2; US7923215B2; US8389228B2; US8399211B2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0193828 A1 20011213; AU 2001275280 B2 20060316; AU 7528001 A 20011217; CA 2411536 A1 20011213; EP 1292279 A1 20030319; EP 1292279 A4 20050112; HU P0302333 A2 20031128; HU P0302333 A3 20050728; IL 153236 A0 20030706; JP 2003535118 A 20031125; PL 363431 A1 20041115; ZA 200210084 B 20031212

DOCDB simple family (application)
US 0118248 W 20010605; AU 2001275280 A 20010605; AU 7528001 A 20010605; CA 2411536 A 20010605; EP 01941973 A 20010605; HU P0302333 A 20010605; IL 15323601 A 20010605; JP 2002501401 A 20010605; PL 36343101 A 20010605; ZA 200210084 A 20021212